JCP Weekly January 15, 2019

Original Research

Psychotic Features in Patients With MDD

Psychotic features within major depressive disorder (MDD) are associated with poor treatment outcome. This article explores whether sociodemographic and clinical characteristics of and pharmacologic treatments received by patients with psychotic MDD differ from those of depressed patients without psychotic features.

DOI: 10.4088/JCP.17m12090 | Posted: 01/15/2019

Commentary

NIMH Drug Trials for Schizophrenia

In this Viewpoint article, Torrey et al call for the National Institute of Mental Health to expand funding for schizophrenia treatment beyond trials that focus on identified biological targets. Specifically, they argue for treatment initiatives directed at normalizing the immune system.

DOI: 10.4088/JCP.18com12597 | Posted: 01/15/2019

Editorial

Peer Review: Who's on the List?

With gratitude, our Editor in Chief honors JCP’s peer reviewers.

DOI: 10.4088/JCP.18ed12690 | Posted: 01/15/2019

Original Research

Identifying Borderline Personality Disorder

Research has shown success in identifying borderline personality disorder (BPD) using the single criterion of affective instability. But can this screening method be used to recognize BPD in individuals who also have mood disorders that share symptoms with BPD? Read this article to learn more.

DOI: 10.4088/JCP.18m12257 | Posted: 01/15/2019

Commentary

NIMH Supports Evidence-Based Treatments for Schizophrenia

In this Viewpoint article, Dr Joshua Gordon, Director of the NIMH, responds to points raised by Torrey et al regarding the decrease in the number of medication trials for schizophrenia and the funding criteria used by the NIMH for such trials.

DOI: 10.4088/JCP.18com12597a | Posted: 01/15/2019

See past JCP Weekly